Bolt Biotherapeutics (NASDAQ:BOLT) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.89 and traded as low as $3.95. Bolt Biotherapeutics shares last traded at $4.21, with a volume of 21,880 shares changing hands.

Wall Street Analysts Forecast Growth

BOLT has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Finally, Rodman & Renshaw began coverage on Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and a consensus price target of $34.67.

Bolt Biotherapeutics Stock Performance

The company’s 50-day moving average price is $4.47 and its two-hundred day moving average price is $4.88. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. The stock has a market cap of $8.50 million, a PE ratio of -0.27 and a beta of 1.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%. On average, equities research analysts forecast that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BOLT. Shay Capital LLC purchased a new position in shares of Bolt Biotherapeutics during the 3rd quarter valued at about $85,000. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics in the 3rd quarter worth approximately $89,000. Renaissance Technologies LLC boosted its stake in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares in the last quarter. Squarepoint Ops LLC boosted its stake in Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares in the last quarter. Finally, T3 Companies LLC bought a new position in Bolt Biotherapeutics during the fourth quarter valued at approximately $208,000. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.